SIGA Technologies Inc. reported a 65% profit drop while retaining cash reserves and issuing special payouts. Profit decline affects earnings outlook but cash position and payouts limit broader damage to trajectory.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2027 | ‡‡‡ |
|
| 2026 | 0.60 |
—
|
| 2025 | 0.60 |
—
|
| 2023 | 0.00 |
—
|
| 2022 | 0.00 |
—
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2016 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 150.15 | 155.40 | 154.97 | 117.58 |
| Receivables | 21.13 | 21.17 | 3.26 | 7.17 |
| Inventory | 64.22 | 49.56 | 49.05 | 41.11 |
| Other | — | — | — | — |
| 238.99 | 231.04 | 212.86 | 170.38 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1.46 | 1.34 | 0.82 | 0.91 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 54.12 | 25.33 | 17.99 | 7.85 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 6.24 | 41.00 | — | — |
—
|
| ’25 | 7.04 | 81.12 | 2.62 | 3.79 |
94.57
|
| ’24 | 25.43 | 21.81 | 10.01 | 81.47 |
138.72
|
| ’23 | 8.32 | 5.88 | 9.24 | 116.48 |
139.92
|
| ’22 | 10.54 | 16.67 | 72.21 | 11.36 |
110.78
|
| ’21 | 4.81 | 8.65 | 4.85 | 115.36 |
133.67
|
| ’20 | 2.62 | 40.35 | 44.26 | 37.73 |
124.96
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (8.66) | 15.17 | — | — |
—
|
| ’25 | 7.06 | 63.08 | (9.81) | (16.86) |
43.47
|
| ’24 | (6.12) | 5.95 | (7.38) | 56.31 |
48.76
|
| ’23 | 24.45 | (3.58) | (5.10) | 79.03 |
94.80
|
| ’22 | 56.71 | (2.21) | (4.78) | (8.11) |
41.61
|
| ’21 | (4.81) | (1.43) | 1.63 | 16.10 |
11.49
|
| ’20 | 3.32 | (9.09) | 31.34 | 45.95 |
71.52
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (8.66) | 15.17 | — | — |
—
|
| ’25 | 7.04 | 63.08 | (10.10) | (16.90) |
43.12
|
| ’24 | (6.12) | 5.95 | (7.41) | 56.29 |
48.72
|
| ’23 | 24.45 | (3.60) | (5.10) | 79.03 |
94.78
|
| ’22 | 56.71 | (2.21) | (4.78) | (8.11) |
41.61
|
| ’21 | (4.82) | (1.44) | 1.63 | 16.08 |
11.44
|
| ’20 | 3.31 | (9.09) | 31.34 | 45.95 |
71.50
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.05) | 0.17 | — | — |
—
|
| ’25 | (0.01) | 0.49 | (0.09) | (0.08) |
0.32
|
| ’24 | 0.14 | 0.03 | 0.02 | 0.63 |
0.82
|
| ’23 | (0.01) | (0.04) | (0.01) | 1.01 |
0.95
|
| ’22 | (0.01) | 0.03 | 0.45 | (0.01) |
0.46
|
| ’21 | (0.02) | 0.00 | (0.04) | 0.98 |
0.91
|
| ’20 | (0.11) | 0.26 | 0.31 | 0.26 |
0.71
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 5.84 | 4.22 | 4.26 | 4.95 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | 26.99 | 8.49 | 12.83 | 9.62 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 39 | 45 | 46 | 49 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.84 | 3.11 | 3.02 | 1.93 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 110.78 | 139.92 | 138.72 | 94.57 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 90.58% | 87.26% | 77.44% | 68.59% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 44.13 | 87.78 | 76.07 | 30.38 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 39.84% | 62.73% | 54.84% | 32.12% | ‡‡‡ | ‡‡‡ | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 33.90 | 68.07 | 59.21 | 23.28 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.52 | 0.54 | 0.54 | 0.56 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.52 | 1.96 | 1.95 | 1.32 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 0.46 | 0.95 | 0.83 | 0.33 | ‡‡‡‡ | ‡‡‡‡ | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.57 | 1.33 | 0.68 | 0.61 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.57 | 1.33 | 0.68 | 0.60 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.33 | 2.76 | 3.03 | 2.78 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 72.93 | 71.36 | 71.25 | 71.53 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Shares
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 14.96 | 6.13 | 7.33 | 18.52 | ‡‡‡‡ | ‡‡‡ | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.63 | 2.97 | 3.09 | 4.62 | ‡‡‡ | ‡‡‡ | — |
PS Ratio
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.01 | 2.11 | 1.98 | 2.20 | ‡‡‡ | ‡‡‡ | — |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.75 | 1.91 | 1.98 | 3.00 | ‡‡‡ | ‡‡‡‡ | — |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.01 | 2.82 | 5.63 | 6.58 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 41.61 | 94.80 | 48.76 | 43.47 | ‡‡‡ | ‡‡‡ | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | (0.02) | (0.04) | (0.35) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 41.61 | 94.78 | 48.72 | 43.12 | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 164.27 | 184.87 | 205.71 | 194.86 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.03 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (96.76) | (150.15) | (155.40) | (154.97) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 170.16 | 196.86 | 215.80 | 198.82 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 16.55% | 30.29% | 23.75% | 10.04% | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 36.36% | 111.88% | 72.41% | 33.78% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 19.68% | 37.09% | 28.70% | 11.23% | — | — | — |
ROE
|
SIGA Technologies shines as a biodefense niche player with its FDA-approved TPOXX antiviral for smallpox, riding the waves of massive but unpredictable U.S. government contracts that deliver blockbuster revenue spikes—think 3,790% growth in 2018—followed by sharp drops. Once a money-losing developer, SIGA has flipped to consistent profitability, boasting 77% gross margins, $59 million net income in 2024, negligible debt, and a fortress-like $155 million net cash position. Yet, its stock mirrors this lumpiness, soaring on mpox hype in 2022 before retrenching, now trading at dirt-cheap multiples like 7.3x P/E and 3.1x P/S.
Looking ahead, analysts eye a 2025 revenue trough to $97 million before a 132% explosion to $226 million in 2026, potentially tripling EPS to $1.51 amid stockpile expansions and global orthopoxvirus threats. With ROE at 29%, zero capex needs, and consensus targets implying 115% upside, SIGA screams undervalued efficiency in a capital-light model—but procurement delays and cycle risks loom large, tempting contrarians to bet on the next boom.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.